Buy & Sell VF Corp (VFC) – VF Corp Price Today
Aura AI Summary
Key Stats
- $7.59BMarket Cap
- Consumer CyclicalSector
- -25.95%3M Drawdown
- $11.47BEnterprise Value
- 1.85%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 58 daysTypical Hold Time
VF Corp (VFC) is currently valued at a market capitalization of $7.59B, with an enterprise value of $11.47B. Over the past 52 weeks, VF Corp has traded between a low of $11.45 and a high of $21.55, highlighting its annual price range. Over the past three months, VF Corp has recorded a drawdown of -25.95%, reflecting recent price volatility. VF Corp offers a dividend yield of 1.85%, with the most recent dividend of $0.09 paid on 10 Mar 26. On average, investors hold VF Corp for approximately 58 days, indicating typical investor behavior on the platform.
About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Most Recent News
Companies like Stripe and SpaceX grow huge without IPOs, using private and secondary markets instead.
Companies such as Stripe, SpaceX, and Databricks are scaling to massive valuations without going public, relying on private funding rounds and secondary markets for liquidity and valuation. Secondary market transactions reached a record $226 billion ...
Tarsus Pharmaceuticals to present at three investor conferences in May 2026
Tarsus Pharmaceuticals announced its management will participate in three upcoming investor conferences in May 2026: Bank of America Securities Health Care Conference on May 12, H.C. Wainwright BioConnect Investor Conference on May 19, and Stifel Vir...
Sanara MedTech faces securities fraud probe after $31.2M loss and program shutdown.
Sanara MedTech Inc. is under investigation by the Schall Law Firm for potential securities law violations after it announced the discontinuation of its Tissue Health Plus program and reported a $31.2 million net loss from discontinued operations, inc...
